Platelet Function Monitoring in Patients With Acute Myocardial Infarction

Inclusion criteria

• Patient >18 years old.
• Patient scheduled to undergo PCI for either stable CAD or AMI:
• Stable CAD defined as negative cardiac isoenzymes prior to the PCI as well as no resting ECG changes indicative of ACS.
• AMI defined as positive cardiac isoenzymes prior to the PCI and/or resting ECG changes indicative of ACS.

• Patients treated with a loading dose of clopidogrel at least 6 hours prior to the blood draw or on a maintenance dose of clopidogrel (of at least 75mg QD) for a minimum of 5 days.

Exclusion criteria

• Known allergies to aspirin, clopidogrel, or prasugrel
• Use of a glycoprotein (GP) IIb/IIIa inhibitor within 8 hours of the blood draw;
• Patient known to be pregnant or lactating;
• Patient with known history of bleeding diathesis or currently active bleeding;
• Platelet count <100,000/mm the day of the blood draw;
• Hematocrit <25% the day of the blood draw;
• On warfarin therapy at the time of the blood draw or the need for warfarin therapy in the subsequent month following the blood draw;
• Known blood transfusion within the preceding 10 days of the blood draw;
• Patient who has received NSAID (not including ASA) within preceding 24 hours of the blood draw;
• Patients presenting with cardiogenic shock;
• Any significant medical condition, which in the investigator's opinion may interfere with the patient's optimal participation in the study.